PFIZER INC
Close on Oct 19, 2026
- Market cap
- $167.78B
- P/E (TTM)
- 38.7
- Dividend yield
- 5.84%
About Pfizer
Pharmaceutical Preparations, SIC 2834
The company operates in the biopharmaceutical sector through its Biopharma segment. It focuses on the discovery, development, licensing, and manufacturing of pharmaceutical therapies, vaccines, and healthcare treatments. Its portfolio and collaborative pipeline include products such as Comirnaty, Prevnar 13, Tukysa, Disitamab Vedotin, Zavzpret, Medrol, and Velsipity, serving patients, hospitals, and healthcare systems through commercial agreements and partnerships.
Operations and tax jurisdictions identified include the United States, Puerto Rico, Ireland, and Singapore. The business utilizes physical infrastructure consisting of land, operational buildings, machinery, and equipment to support clinical trials and production activities. Specific headquarters address information is not stated in the provided text.
Summary of the business section of Pfizer's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PFIZER INC
- Founded
- 1849
- Headquarters
- New York, NY
- Address
- 66 Hudson Boulevard East 10001-2192
- Phone
- (212) 733-2323
- Website
- www.pfizer.com
- Employees
- 75,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, New York, NY
Stock & identifiers
- Ticker
- PFE
- Exchange
- NYSE
- Shares outstanding
- 5.70B, Jul 29, 2026
- Public float
- $138.00B, Jun 29, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 3-for-1, Jul 1, 1999; 2-for-1, Jul 1, 1997; 2-for-1, Jul 3, 1995; 2-for-1, Apr 1, 1991; 2-for-1, Jul 1, 1983
- SEC CIK
- 78003
- CUSIP
- 717081103
- ISIN
- US7170811035
- LEI
- 765LHXWGK1KXCLTFYQ30
- EIN
- 13-5315170
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Albert Bourla | Chairman & CEO, Director | 435,555 |
| Cecile Guegan | Executive Vice President | 149,505 |
| Jennifer B. Damico | SVP & Controller | 28,611 |
| Dennis P. Hancock | Executive Vice President | 47,037 |
| Payal Sahni | Executive Vice President | 97,446 |
| David M. Denton | Chief Financial Officer & EVP | 37,919 |
| Andrew Baum | Executive Vice President | – |
| Christoffel Boshoff | President, R&D | 168,921 |
| Douglas M. Lankler | Executive Vice President | 284,269 |
| Michael McDermott | Executive Vice President | 74,308 |
| Aamir Malik | Executive Vice President | 29,548 |
| Germay Alexandre de | Executive Vice President | 74,377 |
| Lidia Fonseca | Executive Vice President | 46,455 |
| Sally Susman | Executive Vice President | 169,775 |
| Rady A. Johnson | Executive Vice President | 127,242 |
| James Quincey | Director | – |
| Mortimer J. Buckley | Director | 37,632 |
| Joseph Echevarria | Director | – |
| Shantanu Narayen | Director | – |
| James C. Smith | Director | 3,542 |
| Cyrus Taraporevala | Director | 10,000 |
| Ronald E. Blaylock | Director | 71,688 |
| Dan R. Littman | Director | – |
| Susan Desmond-Hellmann | Director | 3,408 |
| Johnson Suzanne M. Nora | Director | 10,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Bourla | $27.59M | $33.71M | $9.55M | $86 | $187 |
| FY2024 Bourla | $24.65M | $38.52M | $8.50M | $86 | $151 |
| FY2023 Bourla | $21.56M | -$62.15M | $6.33M | $88 | $143 |
| FY2022 Bourla | $33.02M | $5.66M | $14.84M | $149 | $133 |
| FY2021 Bourla | $24.35M | $115.18M | $9.29M | $167 | $123 |
| FY2020 Bourla | $21.03M | $29.67M | $9.60M | $103 | $109 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 75,000 people worldwide.”
Corporate history
Events identified from SEC filings